Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q3 2017 (← Previous) (Next →)

Filing Date: Oct 13, 2017

Total Value: $131.4B (100.0% shares, 0.0% debt)

Holdings (8)

— Audentes Therapeutics, Inc. 38.7%

Value $50.86B Shares 1,806,832 Est. Cost $17810.00 Unrealized —

— ImmuneDesign Corp. 17.7%

Value $23.24B Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Achaogen, Inc. 15.7%

Value $20.6B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 10.5%

Value $13.85B Shares 2,215,384 Est. Cost $20.09 Unrealized -68.0%

— Clovis Oncology, Inc. 6.4%

Value $8.385B Shares 101,855 Est. Cost $56000.00 Unrealized —

— CymaBay Therapeutics, Inc. 6.3%

Value $8.263B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— Second Sight Medical Products, Inc. 4.1%

Value $5.392B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— OpGen, Inc. 0.6%

Value $791M Shares 2,554,211 Est. Cost $1150.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Audentes Therapeutics, Inc.	1,806,832	$50.86B	38.7%	$17810.00	—	Common Stock	05070R104
—	ImmuneDesign Corp.	2,208,210	$23.24B	17.7%	$7580.00	—	Common Stock	45252L103
—	Achaogen, Inc.	1,281,152	$20.6B	15.7%	$13050.00	—	Common Stock	004449104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$13.85B	10.5%	$20.09	-68.0%	Common Stock	67576A100
—	Clovis Oncology, Inc.	101,855	$8.385B	6.4%	$56000.00	—	Common Stock	189464100
—	CymaBay Therapeutics, Inc.	1,048,601	$8.263B	6.3%	$9830.00	—	Common Stock	23257D103
—	Second Sight Medical Products, Inc.	4,492,975	$5.392B	4.1%	$1210.00	—	Common Stock	81362J100
—	OpGen, Inc.	2,554,211	$791M	0.6%	$1150.00	—	Common Stock	68373L109